- Report
- March 2024
- 188 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- January 2024
- 175 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- April 2024
- 89 Pages
Global
From €5449EUR$5,600USD£4,668GBP
- Report
- February 2024
- 164 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Drug Pipelines
- April 2024
- 250 Pages
Global
From €2919EUR$3,000USD£2,501GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- January 2024
- 175 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- November 2023
- 182 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Report
- August 2018
- 67 Pages
Global
From €5789EUR$5,950USD£4,959GBP
- Report
- August 2022
- 114 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 200 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- January 2022
- 60 Pages
Global
From €3843EUR$3,950USD£3,292GBP
- Report
- March 2021
- 102 Pages
Global
From €4378EUR$4,500USD£3,751GBP
- Report
- February 2021
- 60 Pages
Global
€1282EUR$1,318USD£1,099GBP
- Report
- August 2022
Global
From €1061EUR$1,090USD£909GBP
- Clinical Trials
- August 2020
- 1552 Pages
Global
From €2432EUR$2,500USD£2,084GBP
- Report
- May 2020
- 40 Pages
Global
From €3887EUR$3,995USD£3,330GBP
- Drug Pipelines
- June 2020
- 1667 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Drug Pipelines
- December 2019
- 80 Pages
Global
From €3405EUR$3,500USD£2,917GBP
Myelodysplastic Syndrome (MDS) is a type of cancer that affects the bone marrow and blood cells. It is a rare disorder that can lead to anemia, infections, and bleeding. Treatment for MDS includes chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat MDS include hypomethylating agents, such as azacitidine and decitabine, and immunomodulatory agents, such as lenalidomide and pomalidomide. These drugs are used to reduce the risk of disease progression and improve the quality of life for patients.
The Myelodysplastic Syndrome Drugs market is a part of the larger Oncology Drugs market. It is a rapidly growing market, driven by the increasing prevalence of MDS and the development of new drugs. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use.
Some of the major companies in the Myelodysplastic Syndrome Drugs market include Celgene Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co. Inc. Show Less Read more